Roivant Sciences: Pay

Roivant Sciences paid its 6 named executives $438.2M in total in FY2024 (Mar). CEO Eric Venker was paid $11.8M of that.

Pay$100 in the stock at the end of FY22 → $455
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Mayukh SukhatmePresident and Chief Investment Officer
FY2024 (Mar)
FY2023 (Mar)Not disclosed
FY2022 (Mar)Not disclosed
FY2021 (Mar)Not disclosed
4 years
Matthew GlineChief Executive Officer
FY2024 (Mar)
FY2023 (Mar)Not disclosed
FY2022 (Mar)Not disclosed
FY2021 (Mar)Not disclosed
FY2020 (Mar)Not disclosed
5 years
Eric VenkerPresident and Immunovant CEO
FY2024 (Mar)
FY2023 (Mar)Not disclosed
FY2021 (Mar)Not disclosed
FY2020 (Mar)Not disclosed
4 years
Rakhi KumarFormer Chief Accounting Officer
FY2024 (Mar)
FY2023 (Mar)Not disclosed
2 years
Richard PulikChief Financial Officer
FY2024 (Mar)
FY2023 (Mar)Not disclosed
2 years
Jennifer HumesChief Accounting Officer
FY2024 (Mar)
1 year

CEO pay against the pay peers

In FY2024 (Mar), the median CEO pay of the 8 peers with pay on file was $15.5M. The CEO of Roivant Sciences was paid $163.3M, 956% above the median.

  1. 1Roivant Sciences
  2. 2United Therapeutics
  3. 3Incyte
  4. 4BridgeBio Pharma
  5. 5Jazz Pharmaceuticals
  6. 6Ionis Pharmaceuticals
  7. 7Halozyme Therapeutics
  8. 8Revolution Medicines
  9. 9Neurocrine Biosciences
  10. 10ACADIA Pharmaceuticals Inc.Not disclosed
  11. 11Amicus Therapeutics, Inc.Not disclosed
  12. 12Apellis Pharmaceuticals, Inc.Not disclosed
  13. 13Arcutis Biotherapeutics, Inc.Not disclosed
  14. 14Ascendis Pharma, Inc.Not disclosed
  15. 15Axsome TherapeuticsNot disclosed
  16. 16Blueprint Medicines CorporationNot disclosed
  17. 17CRISPR Therapeutics, Inc.Not disclosed
  18. 18Cerevel Therapeutics Holdings, Inc.Not disclosed
  19. 19Denali Therapeutics Inc.Not disclosed
  20. 20ExelixisNot disclosed
  21. 21ImmunoGen, Inc.Not disclosed
  22. 22Intra-Cellular Therapies, Inc.Not disclosed
  23. 23Karuna Therapeutics, Inc.Not disclosed
  24. 24MoonLake ImmunotherapeuticsNot disclosed
  25. 25Sarepta Therapeutics, Inc.Not disclosed
  26. 26Vaxcyte, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.